We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the latest close session, Eli Lilly (LLY - Free Report) was up +1.82% at $1,008.39. This move outpaced the S&P 500's daily gain of 0.83%. Elsewhere, the Dow gained 0.5%, while the tech-heavy Nasdaq added 1.38%.
Shares of the drugmaker have depreciated by 6.41% over the course of the past month, underperforming the Medical sector's loss of 3.46%, and the S&P 500's loss of 2.65%.
The investment community will be closely monitoring the performance of Eli Lilly in its forthcoming earnings report. The company is scheduled to release its earnings on April 30, 2026. In that report, analysts expect Eli Lilly to post earnings of $7.5 per share. This would mark year-over-year growth of 124.55%. Meanwhile, our latest consensus estimate is calling for revenue of $17.66 billion, up 38.75% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $34.16 per share and revenue of $81.93 billion, which would represent changes of +41.1% and +25.7%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Eli Lilly. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.24% upward. Eli Lilly is holding a Zacks Rank of #3 (Hold) right now.
From a valuation perspective, Eli Lilly is currently exchanging hands at a Forward P/E ratio of 29. Its industry sports an average Forward P/E of 15.83, so one might conclude that Eli Lilly is trading at a premium comparatively.
One should further note that LLY currently holds a PEG ratio of 1.17. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 2.24.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 200, finds itself in the bottom 19% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Eli Lilly (LLY) Laps the Stock Market: Here's Why
In the latest close session, Eli Lilly (LLY - Free Report) was up +1.82% at $1,008.39. This move outpaced the S&P 500's daily gain of 0.83%. Elsewhere, the Dow gained 0.5%, while the tech-heavy Nasdaq added 1.38%.
Shares of the drugmaker have depreciated by 6.41% over the course of the past month, underperforming the Medical sector's loss of 3.46%, and the S&P 500's loss of 2.65%.
The investment community will be closely monitoring the performance of Eli Lilly in its forthcoming earnings report. The company is scheduled to release its earnings on April 30, 2026. In that report, analysts expect Eli Lilly to post earnings of $7.5 per share. This would mark year-over-year growth of 124.55%. Meanwhile, our latest consensus estimate is calling for revenue of $17.66 billion, up 38.75% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $34.16 per share and revenue of $81.93 billion, which would represent changes of +41.1% and +25.7%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Eli Lilly. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.24% upward. Eli Lilly is holding a Zacks Rank of #3 (Hold) right now.
From a valuation perspective, Eli Lilly is currently exchanging hands at a Forward P/E ratio of 29. Its industry sports an average Forward P/E of 15.83, so one might conclude that Eli Lilly is trading at a premium comparatively.
One should further note that LLY currently holds a PEG ratio of 1.17. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 2.24.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 200, finds itself in the bottom 19% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.